胱抑素C与肌酐估算肾小球滤过率差值及成人糖尿病微血管并发症风险的基于人群队列研究
该前瞻性队列研究纳入英国生物银行25,825例基线无糖尿病微血管并发症的糖尿病患者,中位随访13.6年,发现胱抑素C与肌酐估算肾小球滤过率差值(eGFRdiff)增大与总体糖尿病微血管并发症及其亚型(糖尿病视网膜病变、糖尿病肾病、糖尿病神经病变)风险独立相关。
要点
- eGFRabdiff每降低1个标准差,总体微血管并发症风险升高28%,糖尿病肾病风险升高56%。
- eGFRrediff每降低10%,总体微血管并发症HR为1.16(95%CI 1.14–1.18),糖尿病肾病HR为1.29(95%CI 1.26–1.33)。
- 作者认为监测eGFRdiff对识别糖尿病高危患者有潜在益处。
核心结论
- 较大的eGFRdiff与糖尿病微血管并发症及其亚型风险独立相关。
- 研究结果提示监测eGFRdiff对识别糖尿病高危患者具有潜在益处。
研究设计与样本
- 前瞻性队列研究,纳入英国生物银行2006至2010年基线无糖尿病微血管并发症的25,825例糖尿病患者。
- eGFRdiff分别以绝对值差(eGFRabdiff)和比值(eGFRrediff)计算,通过电子健康记录确定结局,采用Cox比例风险回归模型分析。
主要发现
- 中位随访13.6年期间,5,753例发生糖尿病微血管并发症,包括糖尿病视网膜病变2,752例、糖尿病肾病3,203例、糖尿病神经病变1,149例。
- eGFRabdiff每降低1个标准差,总体微血管并发症风险升高28%,糖尿病视网膜病变风险升高14%,糖尿病肾病风险升高56%,糖尿病神经病变风险升高29%。
- eGFRrediff每降低10%,总体微血管并发症HR为1.16(95%CI 1.14–1.18),糖尿病视网膜病变HR为1.08(95%CI 1.05–1.11),糖尿病肾病HR为1.29(95%CI 1.26–1.33),糖尿病神经病变HR为1.17(95%CI 1.12–1.22)。
- 所有敏感性分析中关联幅度均无实质性改变。
临床怎么用
- 作者认为监测eGFRdiff对识别糖尿病高危患者具有潜在益处。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The impact of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate (eGFRdiff) on diabetic microvascular complications (DMCs) remains unknown. We investigated the associations of eGFRdiff with overall DMCs and subtypes, including diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic neuropathy (DN). RESEARCH DESIGN AND METHODS: This prospective cohort study included 25,825 participants with diabetes free of DMCs at baseline (2006 to 2010) from the UK Biobank. eGFRdiff was calculated using both absolute difference (eGFRabdiff) and the ratio (eGFRrediff) between cystatin C- and creatinine-based calculations. Incidence of DMCs was ascertained using electronic health records. Cox proportional hazards regression models were used to evaluate the associations of eGFRdiff with overall DMCs and subtypes. RESULTS: During a median follow-up of 13.6 years, DMCs developed in 5,753 participants, including 2,752 cases of DR, 3,203 of DKD, and 1,149 of DN. Each SD decrease of eGFRabdiff was associated with a 28% higher risk of overall DMCs, 14% higher risk of DR, 56% higher risk of DKD, and 29% higher risk of DN. For each 10% decrease in eGFRrediff, the corresponding hazard ratios (95% CIs) were 1.16 (1.14, 1.18) for overall DMCs, 1.08 (1.05, 1.11) for DR, 1.29 (1.26, 1.33) for DKD, and 1.17 (1.12, 1.22) for DN. The magnitude of associations was not materially altered in any of the sensitivity analyses. CONCLUSIONS: Large eGFRdiff was independently associated with risk of DMCs and its subtypes. Our findings suggested monitoring eGFRdiff in the diabetes population has potential benefit for identification of high-risk patients.
引用
- He D, Gao B, Wang J, et al. The Difference Between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and Risk of Diabetic Microvascular Complications Among Adults With Diabetes: A Population-Based Cohort Study. Diabetes Care. 2024. PMID: 38470988. doi:10.2337/dc23-2364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。